Overview

Study of Long-Term Efficacy and Safety of LIB003 in CVD or High Risk for CVD Patients Needing Further LDL-C Reduction

Status:
Enrolling by invitation

Trial end date:
2022-12-31

Target enrollment:

Participant gender:

Summary

This study is to assess LDL-C reductions at Week 52 with monthly (Q4W [≤31 days]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with CVD, or at high risk for CVD, on a stable diet and oral LDL-C lowering drug therapy

Phase:

Phase 3

Details

Lead Sponsor:

LIB Therapeutics LLC

Collaborator:

Medpace, Inc.